Literature DB >> 17607371

Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma.

Yuichi Sanada1, Kazuhiro Yoshida, Masahiro Ohara, Yasuhiro Tsutani.   

Abstract

The purpose of this study was to clarify the role of orotate phosphoribosyltransferase (OPRT) in the progression of hepatobiliary and pancreatic carcinomas. Representative sections from 8 surgically resected pancreatic carcinomas, 5 gallbladder carcinomas and 19 hepatocellular carcinomas (HCCs) were examined microscopically. Sites of pancreatic intraepithelial neoplasia (PanIN) were counted, and histologic subtypes of invasive ductal carcinoma of the pancreas (IDC) were determined. Gallbladder carcinomas and HCCs were examined histologically, and the subtypes and spread patterns were assessed. Expression of OPRT was examined immunohistochemically. A total of 75 PanINs were identified. Expression of OPRT increased as lesions progressed from early to high-grade PanINs (PanIN-1A and -1B versus PanIN-2 and -3, p=0.0004). Three (37.5%) of the 8 pancreatic IDCs were positive for OPRT. In the remaining 5 cases, OPRT was expressed only in the neoplastic ducts adjacent to PanIN-3s. In gallbladder carcinomas, mucosal neoplastic epithelium showed dense cytoplasmic expression in 4 of the 5 cases, but expression was absent in the deeply invasive lesions. Among HCCs, 15 of the 19 cases were negative for OPRT in the central area of the tumor, but 8 of the 19 cases expressed OPRT in vascularly invasive lesions. Our data suggest that OPRT is involved in early events of pancreatic and gallbladder carcinogenesis and invasion of HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607371     DOI: 10.1007/bf02893485

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  22 in total

1.  Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells.

Authors:  S Hidaka; T Yasutake; M Fukushima; H Yano; M Haseba; T Tsuji; T Sawai; H Yamaguchi; T Nakagoe; H Ayabe; Y Tagawa
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

2.  Preparation of anti-orotate phosphoribosyltransferase antibody and its application to immunochemical detection in human tumor cells.

Authors:  Kazuki Sakamoto; Yoshikazu Sugimoto; Kazutaka Miyadera; Toshinori Oka; Masakazu Fukushima
Journal:  Int J Mol Med       Date:  2005-08       Impact factor: 4.101

3.  Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.

Authors:  Takumi Ochiai; Michiharu Sugitani; Kazuhiko Nishimura; Hajime Noguchi; Tsuyoshi Okada; Masakazu Ouchi; Masaki Yamada; Masayuki Kitajima; Yuko Tsuruoka; Yuka Takahashi; Shunji Futagawa
Journal:  Oncol Rep       Date:  2005-10       Impact factor: 3.906

4.  Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Hajime Noguchi; Masayuki Kitajima; Yuko Tsuruoka; Yuka Takahashi; Akira Tsukada; Emiko Watanabe; Isao Nagaoka; Shunji Futagawa
Journal:  J Surg Oncol       Date:  2006-07-01       Impact factor: 3.454

5.  [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].

Authors:  Hideyuki Ishida; Kazuo Shirakawa; Tomonori Ohsawa; Jun Sobajima; Yoichi Hayashi; Hiroshi Nakada; Masaru Yokoyama; Daijo Hashimoto
Journal:  Gan To Kagaku Ryoho       Date:  2005-11

6.  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

7.  Pancreatic intraepithelial neoplasia.

Authors:  Kyoichi Takaori; Ralph H Hruban; Anirban Maitra; Nobuhiko Tanigawa
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

8.  Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components.

Authors:  Yuichi Sanada; Kazuhiro Yoshida; Masahiro Ohara; Mamoru Oeda; Kazuo Konishi; Yasuhiro Tsutani
Journal:  Pancreas       Date:  2006-03       Impact factor: 3.327

9.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

Authors:  J Nakano; C Huang; D Liu; D Masuya; T Nakashima; H Yokomise; M Ueno; H Wada; M Fukushima
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

Review 10.  Chemoprevention of pancreatic cancer: a review of the molecular pathways involved, and evidence for the potential for chemoprevention.

Authors:  H Doucas; G Garcea; C P Neal; M M Manson; D P Berry
Journal:  Pancreatology       Date:  2006-07-13       Impact factor: 3.996

View more
  5 in total

1.  Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma.

Authors:  Wenjun Wang; Zhu-lin Yang; Jie-qiong Liu; Song Jiang; Xiong-ying Miao
Journal:  Tumour Biol       Date:  2011-11-12

2.  Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma.

Authors:  Dong-cai Liu; Zhu-lin Yang; Song Jiang
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

3.  Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.

Authors:  Guo-shun Shu; Fang Lv; Zhu-lin Yang; Xiong-ying Miao
Journal:  Int J Clin Oncol       Date:  2012-06-21       Impact factor: 3.402

4.  Periampullary localized pancreatic intraepithelial neoplasia-3 (PanIN-3): evaluation with contrast-enhanced MR cholangiography (MRCP).

Authors:  Oktay Algin; Evrim Ozmen; Pamir Eren Ersoy; Mustafa Karaoglanoglu
Journal:  Radiol Oncol       Date:  2011-11-16       Impact factor: 2.991

5.  Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma.

Authors:  Qiong Zou; Zhu-lin Yang; Yuan Yuan; Jing-he Li; Lu-feng Liang; Gui-xiang Zeng; Sen-lin Chen
Journal:  World J Surg Oncol       Date:  2013-06-19       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.